Unanswered questions regarding the management of sunitinib-induced hypothyroidism.

Suppr

超能文献

作者信息

Garfield David, Hercbergs Aleck, Davis Paul

机构信息

Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80209, USA.

出版信息

Nat Clin Pract Oncol. 2007 Dec;4(12):674. doi: 10.1038/ncponc0998. Epub 2007 Oct 23.

DOI:10.1038/ncponc0998

PMID:17955044

Abstract

摘要

相似文献

Unanswered questions regarding the management of sunitinib-induced hypothyroidism.

Nat Clin Pract Oncol. 2007 Dec;4(12):674. doi: 10.1038/ncponc0998. Epub 2007 Oct 23.

Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

J Natl Cancer Inst. 2007 Jun 20;99(12):975-6; author reply 976-7. doi: 10.1093/jnci/djm008. Epub 2007 Jun 12.

Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

J Natl Cancer Inst. 2007 Jun 20;99(12):974-5; author reply 976-7. doi: 10.1093/jnci/djm006. Epub 2007 Jun 12.

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

J Natl Cancer Inst. 2007 Jan 3;99(1):81-3. doi: 10.1093/jnci/djk008.

Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.

Ann Intern Med. 2006 Nov 7;145(9):I44. doi: 10.7326/0003-4819-145-9-200611070-00004.

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

Ann Intern Med. 2006 Nov 7;145(9):660-4. doi: 10.7326/0003-4819-145-9-200611070-00008.

How does sunitinib cause hypothyroidism?

Thyroid. 2010 Mar;20(3):243-4. doi: 10.1089/thy.2010.1620.

Acute severe hypothyroidism induced by sunitinib.

Radiother Oncol. 2008 Oct;89(1):124-5. doi: 10.1016/j.radonc.2008.05.007. Epub 2008 May 24.

Documentation of thyroid function in clinical studies with sunitinib: why does it matter?

J Clin Oncol. 2008 Nov 1;26(31):5131-2; author reply 5132-3. doi: 10.1200/JCO.2008.18.8680. Epub 2008 Sep 29.

Sunitinib adverse event: oral bullous and lichenoid mucositis.

Ann Pharmacother. 2009 Mar;43(3):546-7. doi: 10.1345/aph.1L592. Epub 2009 Feb 24.

引用本文的文献

Impact of Tyrosine Kinase Inhibitors on Thyroid Function in Chronic Myeloid Leukemia: A Systematic Review.

Cureus. 2025 Jun 1;17(6):e85196. doi: 10.7759/cureus.85196. eCollection 2025 Jun.

Detection of strain types and analysis of risk factors among subjects from Hainan Province, China.

J Int Med Res. 2024 May;52(5):3000605241253454. doi: 10.1177/03000605241253454.

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.

World J Gastroenterol. 2018 Dec 14;24(46):5189-5202. doi: 10.3748/wjg.v24.i46.5189.

Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Nat Rev Clin Oncol. 2016 Apr;13(4):209-27. doi: 10.1038/nrclinonc.2015.213. Epub 2015 Dec 31.

Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment.

Biomed Res Int. 2013;2013:725410. doi: 10.1155/2013/725410. Epub 2013 Oct 27.

Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.

Target Oncol. 2011 Dec;6(4):217-26. doi: 10.1007/s11523-011-0197-2. Epub 2011 Nov 19.

Thyroid dysfunction from antineoplastic agents.

J Natl Cancer Inst. 2011 Nov 2;103(21):1572-87. doi: 10.1093/jnci/djr373. Epub 2011 Oct 18.

Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors.

Br J Cancer. 2010 Apr 13;102(8):1309-10; author reply 1311. doi: 10.1038/sj.bjc.6605628. Epub 2010 Mar 30.

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

Nat Rev Clin Oncol. 2009 Apr;6(4):219-28. doi: 10.1038/nrclinonc.2009.4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Unanswered questions regarding the management of sunitinib-induced hypothyroidism.

Nat Clin Pract Oncol. 2007 Dec;4(12):674. doi: 10.1038/ncponc0998. Epub 2007 Oct 23.

Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

J Natl Cancer Inst. 2007 Jun 20;99(12):975-6; author reply 976-7. doi: 10.1093/jnci/djm008. Epub 2007 Jun 12.

Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

J Natl Cancer Inst. 2007 Jun 20;99(12):974-5; author reply 976-7. doi: 10.1093/jnci/djm006. Epub 2007 Jun 12.

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

J Natl Cancer Inst. 2007 Jan 3;99(1):81-3. doi: 10.1093/jnci/djk008.

Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.

Ann Intern Med. 2006 Nov 7;145(9):I44. doi: 10.7326/0003-4819-145-9-200611070-00004.

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

Ann Intern Med. 2006 Nov 7;145(9):660-4. doi: 10.7326/0003-4819-145-9-200611070-00008.

How does sunitinib cause hypothyroidism?

Thyroid. 2010 Mar;20(3):243-4. doi: 10.1089/thy.2010.1620.

Acute severe hypothyroidism induced by sunitinib.

Radiother Oncol. 2008 Oct;89(1):124-5. doi: 10.1016/j.radonc.2008.05.007. Epub 2008 May 24.

Documentation of thyroid function in clinical studies with sunitinib: why does it matter?

J Clin Oncol. 2008 Nov 1;26(31):5131-2; author reply 5132-3. doi: 10.1200/JCO.2008.18.8680. Epub 2008 Sep 29.

Sunitinib adverse event: oral bullous and lichenoid mucositis.

Ann Pharmacother. 2009 Mar;43(3):546-7. doi: 10.1345/aph.1L592. Epub 2009 Feb 24.

引用本文的文献

Impact of Tyrosine Kinase Inhibitors on Thyroid Function in Chronic Myeloid Leukemia: A Systematic Review.

Cureus. 2025 Jun 1;17(6):e85196. doi: 10.7759/cureus.85196. eCollection 2025 Jun.

Detection of strain types and analysis of risk factors among subjects from Hainan Province, China.

J Int Med Res. 2024 May;52(5):3000605241253454. doi: 10.1177/03000605241253454.

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.

World J Gastroenterol. 2018 Dec 14;24(46):5189-5202. doi: 10.3748/wjg.v24.i46.5189.

Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Nat Rev Clin Oncol. 2016 Apr;13(4):209-27. doi: 10.1038/nrclinonc.2015.213. Epub 2015 Dec 31.

Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment.

Biomed Res Int. 2013;2013:725410. doi: 10.1155/2013/725410. Epub 2013 Oct 27.

Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management.

Target Oncol. 2011 Dec;6(4):217-26. doi: 10.1007/s11523-011-0197-2. Epub 2011 Nov 19.

Thyroid dysfunction from antineoplastic agents.

J Natl Cancer Inst. 2011 Nov 2;103(21):1572-87. doi: 10.1093/jnci/djr373. Epub 2011 Oct 18.

Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors.

Br J Cancer. 2010 Apr 13;102(8):1309-10; author reply 1311. doi: 10.1038/sj.bjc.6605628. Epub 2010 Mar 30.

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

Nat Rev Clin Oncol. 2009 Apr;6(4):219-28. doi: 10.1038/nrclinonc.2009.4.